Emma Catherine Morris

Emma Catherine Morris

Auto-generated profile, based on publicly available information

Emma Catherine Morris

UCL Institute of Immunity and Transplantation, UCL, London, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2021 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
EMEmma C. Morris
Emma C. Morris
SNSattva S. Neelapu
Sattva S. Neelapu
TGTheodoros Giavridis
Theodoros Giavridis
MSMichel Sadelain
Michel Sadelain

27 January 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DKDonald Kohn
Donald Kohn
CBClaire Booth
Claire Booth
EKElizabeth M. Kang
Elizabeth M. Kang
SPSung-Yun Pai
Sung-Yun Pai
KSKit L. Shaw
Kit L. Shaw
ATAdrian J. Thrasher
Adrian J. Thrasher

23 August 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
AKAlan Kennedy
Alan Kennedy
EWErin Waters
Erin Waters
BRBehzad Rowshanravan
Behzad Rowshanravan
CHClaudia Hinze
Claudia Hinze
CWCayman Williams
Cayman Williams
DSDavid M. Sansom
David M. Sansom
CD28 and CTLA-4 (CD152) play essential roles in regulating T cell immunity, balancing the activation and inhibition of T cell responses, respectively. Although both receptors share the same ligands, CD80 and CD86, the specific requirement for two distinct ligands remains obscure. In the present study, we demonstrate that, although CTLA-4 targets both CD80 and CD86 for destruction via transendocytosis, this process results in separate fates for CTLA-4 itself. In the presence of CD80, CTLA-4 remained ligand bound, and was ubiquitylated and trafficked via late endosomes and lysosomes. In contrast, in the presence of CD86, CTLA-4 detached in a pH-dependent manner and recycled back to the cell surface to permit further transendocytosis. Furthermore, we identified clinically relevant mutations that cause autoimmune disease, which selectively disrupted CD86 transendocytosis, by affecting either CTLA-4 recycling or CD86 binding. These observations provide a rationale for two distinct ligands and show that defects in CTLA-4-mediated transendocytosis of CD86 are associated with autoimmunity.

1 June 2005 in The Lancet
Verified
Journal Article
Closed access
KPKarl S Peggs
Karl S Peggs
AHAnn Hunter
Ann Hunter
RCRajesh Chopra
Rajesh Chopra
APAnne Parker
Anne Parker
PMPremini Mahendra
Premini Mahendra
SMStephen Mackinnon
Stephen Mackinnon

15 December 2004 in Blood
Verified
Journal Article
Closed access
PDF file
EMEmma Morris
Emma Morris
KTKirsty Thomson
Kirsty Thomson
CCCharles Craddock
Charles Craddock
PMPrem Mahendra
Prem Mahendra
DMDonald Milligan
Donald Milligan
SMStephen Mackinnon
Stephen Mackinnon
We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10). Thirty-seven patients had previously received autografts, and 21 were in complete remission (CR) at transplantation. Conditioning therapy consisted of alemtuzumab, fludarabine, and melphalan. Sixty-five patients received peripheral blood stem cells (PBSCs) from HLA-identical siblings, and 23 received bone marrow (BM) from matched unrelated donors. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporin A. Grade III-IV acute GVHD developed in 4 patients, and chronic GVHD developed in 6 patients. With a median follow-up of 36 months (range, 18-60 months), the actuarial overall survival (OS) rates at 3 years were 34% for HG-NHL, 60% for MCL, and 73% for LG-NHL (P < .001). The 100-day and 3-year transplant-related mortality (TRM) rates for patients with LG-NHL were 2% and 11%, respectively, and were better (P = .01) than they were for patients with HG-NHL (27% and 38%, respectively). The actuarial current progression-free survival (PFS) rate at 3 years, including the rate for patients who achieved remission after donor lymphocyte infusion (DLI) for progression, was 65% for LG-NHL, 50% for MCL, and 34% for HG-NHL (P = .002). Twenty-one patients underwent DLI for matched related donor (MD)-persistent disease or relapse, and 15 underwent DLI for mixed hematopoietic chimerism. Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable. (Blood. 2004;104:3865-3871)

15 February 2004 in Blood
Verified
Journal Article
Closed access
PDF file
KPKarl S. Peggs
Karl S. Peggs
KTKirsty Thomson
Kirsty Thomson
DHDaniel P. Hart
Daniel P. Hart
JGJohanne Geary
Johanne Geary
EMEmma C. Morris
Emma C. Morris
SMStephen Mackinnon
Stephen Mackinnon
Data on the application of donor lymphocyte infusions (DLIs) following reduced-intensity transplantation (RIT) remain limited. Persistence of host antigen-presenting cells might increase the efficacy or toxicity of cellular immunotherapies. We report the results of dose-escalating DLIs in 46 patients undergoing RIT, who received a total of 109 infusions to treat mixed chimerism or residual or progressive disease. Diagnoses were myeloma (n = 19), Hodgkin lymphoma (n = 13), non-Hodgkin lymphoma (n = 10), and other (n = 4). Thirty-two had an HLA-matched family donor and 14 an unrelated donor. Grades II to IV graft-versus-host disease (GVHD) occurred in 5 sibling and 7 unrelated donor recipients. GVHD was more common (P = .002), occurred at lower T-cell doses, and was more severe in the unrelated donor cohort. Conversion from mixed to multilineage full donor chimerism occurred in 30 of 35 evaluable patients. Presence of mixed chimerism in the granulocyte lineage at the time of DLI did not predict for chimerism response or GVHD. Disease responses occurred in 63% of patients with myeloma and 70% of those with Hodgkin lymphoma and were not predicted by changes in chimerism. These data support the presence of clinically relevant graft-versus-Hodgkin activity and indicate that DLI may be associated with a significantly increased toxicity in unrelated compared to sibling donor transplant recipients receiving identical treatment protocols.